Disclosed are compounds having the formula: ##STR00001## wherein X, Y, Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, R.sup.5, R.sup.A, m, A. L, and B are as defined herein, and methods of making and using the same.

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

A topical composition for pain relief comprising phytocannabinoids and a carrier vehicle for the phytocannabinoids, which include tetrahydrocannabinol THC and cannabidiol CBD present in amounts up to 25%, delivered to a user's skin and/or lips to alleviate pain.

A topical composition for pain relief comprising phytocannabinoids and a carrier vehicle for the phytocannabinoids, which include tetrahydrocannabinol THC and cannabidiol CBD present in amounts up to 25%, delivered to a user's skin and/or lips to alleviate pain.

The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives.

The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.

Provided herein is a pharmaceutical composition comprising a compound having the structural formula

##STR00001##

wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.

The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.

There are described ROR modulators of the formula (I), ##STR00001##
and formula (II) ##STR00002##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR activity, for example, autoimmune and/or inflammatory disorders.

Methods and compositions for reducing the risk of cardiovascular, cerebrovascular, or renovascular adverse events are provided. Generally, the methods include administering to a subject taking an NSAID a therapeutically effective amount of a misoprostol compound. The methods can also include administering to a subject in need thereof a therapeutically effective amount of an NSAID and therapeutically effective amount of a misoprostol compound.